I, Aman Kumar (M. Pharm), am a researcher in the field of Pharmaceutics with research interests in advanced pharmaceutical formulation development and novel drug delivery systems. My research work mainly focuses on the design and optimization of nanotechnology-based drug delivery systems to enhance drug solubility, stability, bioavailability, and therapeutic effectiveness. I have completed B. Pharm and M. Pharm (Pharmaceutics) and have been actively involved in pharmaceutical research focusing on innovative formulation strategies. My current research work is primarily focused on the development of nanoemulsion-based drug delivery systems for the treatment of Rheumatoid Arthritis using Methotrexate with Beta-Cyclodextrin to enhance drug solubility and transdermal delivery efficiency. The work involves formulation optimization using pseudo-ternary phase diagrams, nanoemulsion characterization, and evaluation through in-vitro, ex-vivo, and in-vivo studies. My research work is primarily focused on drug delivery and advanced formulation development of different Novel Drug Delivery Systems such as liposomes, nanoparticles, nanoemulsions, and nanogels using modern pharmaceutical approaches including Quality by Design (QbD) strategies. I have achieved several research milestones as follows: Authored multiple review articles in pharmaceutical sciences covering the pharmacological potential of Berberine, the pathophysiology and treatment approaches of Raynaud’s Phenomenon, the pharmaceutical applications of Cyclodextrins, and signaling pathway modulation by Quercetin. Conducted research work focused on nanotechnology-based drug delivery systems and emerging nanomaterials such as MXenes for advanced therapeutic applications. Presented research work in pharmaceutics and drug delivery systems at academic research competitions and conferences. Actively engaged in research related to nanoformulations for inflammatory diseases such as Psoriasis and Rheumatoid Arthritis with the aim of improving therapeutic outcomes through innovative pharmaceutical technologies.